Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413477 | 1.00 | PNMT (1.00) | PNMTSLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL3058411 | 1.00 | PNMT (1.00) | PNMTSLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL17407613 | 0.84 | PNMT (0.72) | PNMTSLC6A2SLC6A3TAAR1SLC6A4 | |
| SCHEMBL5018935 | 0.83 | PNMT (0.70) | PNMTSLC6A2SLC6A3TAAR1SLC6A4 | |
| SCHEMBL786411 | 0.82 | PNMT (0.70) | PNMTSLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL14478214 | 0.82 | PNMT (0.70) | PNMTSLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL16649712 | 0.82 | PNMT (0.70) | PNMTSLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL14944872 | 0.82 | PNMT (0.70) | PNMTSLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL10599873 | 0.81 | PNMT (0.68) | PNMTSLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL8893657 | 0.81 | PNMT (0.68) | PNMTSLC6A2SLC6A3TAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | claimed |
| EP-1917006-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT Patent & Licence Trading Ltd. (GB) | 2008-05-07 | — | — | EP | claimed |
| WO-2006136454-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD. (GB) | 2006-12-28 | — | — | WO | claimed |
| US-12595269-B2 | Morpholine-like monoamine releasers | Solvonis Therapeutics Ireland Holdings Limited (IE) | 2026-04-07 | — | — | US | disclosed |
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-06-05 | — | — | US | disclosed |
| EP-4479404-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | Awakn Ls Europe Holdings Limited (IE) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023156565-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2023-08-24 | — | — | WO | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | PNMT 958/4885SLC6A2 3436/4885SLC6A3 3411/4885 |
| US-12595269-B2 | Morpholine-like monoamine releasers | HTR3B, HTR3D, SLC6A3 | PNMT 33/4885SLC6A2 19/4885SLC6A3 3/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | PNMT 916/4885SLC6A2 3422/4885SLC6A3 3352/4885 |
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | PNMT, SLC18A2, HTR2C | PNMT 1/4885SLC6A2 45/4885SLC6A3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.